Page last updated: 2024-11-13
culicinin d
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
culicinin D: an antitumor peptaibol produced by the fungus Culicinomyces clavisporus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44583847 |
| CHEMBL ID | 502978 |
| MeSH ID | M0499644 |
Synonyms (2)
| Synonym |
|---|
| CHEMBL502978 |
| culicinin d |
Research Excerpts
Overview
Culicinin D is a 10 amino acid peptaibol containing a rare and synthetically challenging (2S,4S,6R)-AHMOD residue. It exhibits potent antiproliferative activity against MDA-MB-468 cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Culicinin D is a 10 amino acid peptaibol containing a rare and synthetically challenging (2S,4S,6R)-AHMOD residue, that exhibits potent antiproliferative activity against MDA-MB-468 cells. " | ( Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues. Abbattista, MR; Brimble, MA; Harris, PWR; Kavianinia, I; Patterson, AV; Smaill, JB; Stubbing, LA, 2019) | 2.22 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID376647 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as inhibition of S6K phosphorylation after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376649 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as inhibition of 4EBP1 phosphorylation after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376648 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as inhibition of S6 phosphorylation after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376644 | Growth inhibition of PTEN deficient human MDA468 cells after 3 days by MTS assay | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376651 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as increase in p27Kip1 level at 0.01 to 0.1 ug/mL after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376650 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as inhibition of cyclin D3 level at 0.01 to 0.1 ug/mL after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376646 | Effect on PI3K/AKT/mTOR pathway in PTEN deficient human MDA468 cells assessed as phosphorylated AKT level at 0.01 to 0.1 ug/mL after 16 hrs by Western blot | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| AID376645 | Growth inhibition of human MDA435 overexpressing PTEN after 3 days by MTS assay | 2006 | Journal of natural products, May, Volume: 69, Issue:5 | Culicinin D, an antitumor peptaibol produced by the fungus Culicinomyces clavisporus, strain LL-12I252. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.26) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||